CTOs on the Move

MaxCyte

www.maxcyte.com

 
MaxCyte is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.maxcyte.com
  • 22 Firstfield Road Suite 110
    Gaithersburg, MD USA 20878
  • Phone: 301.944.1700

Executives

Name Title Contact Details

Similar Companies

BioAmber

BioAmber is a renewable chemistry company. We use agricultural crops and transform them into green chemicals that directly substitute chemicals derived from oil. BioAmber combines industrial biotechnology and chemical catalysis into a process that offers a better carbon footprint than petrochemicals. In addition to moving away from petroleum, our process consumes CO2, directly reducing greenhouse gas emissions and aiding in the fight against global warming. Bioamber is today the only producer of bio-succinic acid, a chemical building block used in a number of applications, such as plastics, polyurethane, solvents, personal care, plasticisers, etc.

AviadoBio

At AviadoBio our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company`s technology is based on pioneering research from King`s College London and the UK Dementia Research Institute.

Pulmotect

Pulmotect has developed PUL-042, an inhaled therapeutic which aims to boost the body`s innate immune system resulting in highly-targeted lung protection against all major classes of pathogens including bacteria, fungi, and viral pathogens.

Leesville Rehabilitation Hospital

Leesville Rehabilitation Hospital is a Leesville, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Artizan Biosciences

Artizan Biosciences, Inc. is a biotechnology company with a mission to restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies. We are leveraging our proprietary IgA-SEQ™ technology platform to distinguish disease-driving bacteria from the intestinal microbiota with the goal of developing new and potentially curative treatments.